ArticleJournal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics2013
Hydrosilylated porous silicon particles function as an intravitreal drug delivery system for daunorubicin.
Article in Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed.
- Effective treatment of retinal neovascular leakage with fusogenic porous silicon nanoparticles delivering VEGF-siRNA.Nanomedicine (London, England) · 2022Article
- Intravitreal safety profiles of sol-gel mesoporous silica microparticles and the degradation product (Si(OH)Drug delivery · 2020Article
- Porous silicon based intravitreal platform for dual-drug loading and controlled release towards synergistic therapy.Drug delivery · 2018Article
- A sustained intravitreal drug delivery system with remote real time monitoring capability.Acta biomaterialia · 2015Article
- Mechanism of erosion of nanostructured porous silicon drug carriers in neoplastic tissues.Nature communications · 2015Article
- Intravitreal controlled release of dexamethasone from engineered microparticles of porous silicon dioxide.Experimental eye research · 2014Article
- Porous silicon oxide-PLGA composite microspheres for sustained ocular delivery of daunorubicin.Acta biomaterialia · 2014Article
- Oxidation-Induced Trapping of Drugs in Porous Silicon Microparticles.Chemistry of materials : a publication of the American Chemical Society · 2014Article
- Tunable sustained intravitreal drug delivery system for daunorubicin using oxidized porous silicon.Journal of controlled release : official journal of the Controlled Release Society · 2014Article
- Sustained delivery of a HIF-1 antagonist for ocular neovascularization.Journal of controlled release : official journal of the Controlled Release Society · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
purposeTo evaluate in vivo ocular safety of an intravitreal hydrosilylated porous silicon (pSi) drug delivery system along with the payload of daunorubicin (DNR).
methodspSi microparticles were prepared from the electrochemical etching of highly doped, p-type Si wafers and an organic linker was attached to the Si-H terminated inner surface of the particles by thermal hydrosilylation of undecylenic acid. DNR was bound to the carboxy terminus of the linker as a drug-loading strategy. DNR release from hydrosilylated pSi particles was confirmed in the excised rabbit vitreous using liquid chromatography-electrospray ionization-multistage mass spectrometry. Both empty and DNR-loaded hydrosilylated pSi particles were injected into the rabbit vitreous and the degradation and safety were studied for 6 months.
resultsThe mean pSi particle size was 30×46×15 μm with an average pore size of 15 nm. Drug loading was determined as 22 μg per 1 mg of pSi particles. An ex vivo drug release study showed that intact DNR was detected in the rabbit vitreous. An in vivo ocular toxicity study did not reveal clinical or pathological evidence of any toxicity during a 6-month observation. Hydrosilylated pSi particles, either empty or loaded with DNR, demonstrated a slow elimination kinetics from the rabbit vitreous without ocular toxicity.
conclusionsHydrosilylated pSi particles can host a large quantity of DNR by a covalent loading strategy and DNR can be slowly released into the vitreous without ocular toxicity, which would appear if an equivalent quantity of free drug was injected.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.